07:28 AM EDT, 09/16/2024 (MT Newswires) -- Merck ( MRK ) said Saturday that results from a phase 3 trial showed that Keytruda with chemoradiotherapy reduced the risk of death in patients newly diagnosed with high-risk locally advanced cervical cancer compared with chemoradiotherapy alone.

Merck ( MRK ) said Keytruda combined with chemoradiotherapy decreased the risk of death by 33% at a median follow-up of 29.9 months while the 36-month overall survival rate was 82.6% for patients who received the combination therapy compared with chemoradiotherapy alone.

The company also said no new safety signals were observed in the trial, which is one of four phase 3 trials of a Keytruda-based therapy in an early stage of cancer to show an overall survival benefit.

Price: 115.56, Change: +0.47, Percent Change: +0.41